HuagongsheHuagongshe Chemistry Print Report · For research reference only
1-(2-Bromoethyl)-4-methoxybenzene → 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(4-methoxyphenethyl)-5,5-dimethylimidazolidine-2,4-dione
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | 1-(2-Bromoethyl)-4-methoxybenzene | HCID 84427 | — |
| Reactant | 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione | HCID 59524388 | — |
| Product | 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-1-(4-methoxyphenethyl)-5,5-dimethylimidazolidine-2,4-dione | HCID 53373640 | — |
Reaction Steps
Prepared as in Example 12-16 from 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)-5,5-dimethylimidazolidine-2,4-dione (Example 12-16a) and 1-(2-bromoethyl)-4-methoxybenzene. MS 438 (MH+). The title compound was shown to inhibit hT2R08 bitter receptor and had an IC50 of 0.12 μM.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US09247759B2 |
| Source dataset | uspto-grants-2016_02 |
| ORD ID | ord-4fd76bbfc1524e1cb2ef30279341f620 |
| Source note | uspto-grants-2016_02 |